Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Company: FARON PHARMACEUTICALS OY Date: 2025-05-15 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 National Storage Mechanism | Additional information

Faron Pharmaceuticals

15 May 2025 06:00 UTC

- - -

# Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd | Press Release | May 15, 2025 at 09:00:00 EEST

***Overcoming immune resistance in HR-MDS: Detailed safety and efficacy Phase II data on bexmarilimab to be presented at EHA 2025***

**TURKU, FINLAND** – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, today announced that data from its ongoing BEXMAB study evaluating *bexmarilimab* in patients with high-risk myelodysplastic syndromes (HR-MDS) have been accepted for an oral presentation at the 30th European Hematology Association’s (EHA 2025) Congress, taking place in Milan from June 12–15, 2025.

The oral presentation will feature detailed efficacy and safety results from the study of *bexmarilimab* in combination with standard-of-care (azacitidine) in frontline with HR-MDS and those with refractory or relapsed HR-MDS who have failed hypomethylating agent (HMA) therapies (r/r MDS). This follows the recent positive findings of the [Phase II data f](https://faron.com/releases-and-publications/inside-information-faron-announces-positive-phase-ii-results-in-higher-risk-myelodysplastic-syndrome/)rom the BEXMAB study, and reaffirms bexmarilimab’s mechanism of action and its potential in improving outcomes for patients with MDS.

Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, said: “We are thrilled to see *bexmarilimab’s* data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO. This continued momentum reinforces our belief that *bexmarilimab* holds real promise as a much-needed therapeutic option for patients with higher-risk MDS, a rare and challenging condition with few effective treatments. We remain deeply committed to advancing its development and bringing meaningful innovation to those who need it most.”

The details of the oral presentation are as follows:

**Presentation title:** Efficacy of Macrophage Checkpoint Clever-1 Inhibition with *bexmarilimab* plus Azacitidine in Myelodysplastic Syndrome: Results from the Ph1/2 BEXMAB Study

**Session:** Oral presentation 

**Presenter:** Dr. Mika Kontro, MD, PhD

**Date and Time:** 15 June 2025 11:00 – 12:15 CEST

**Location:** Milan, Italy

**Abstract no:** S178

Further details will be shared closer to the conference dates.

**For more information, please contact:**

|     |     |
| --- | --- |
| **IR Partners, Finland**  <br><br>**(Media)**  <br><br>Riina Tuominen  <br><br>Kare Laukkanen | +358 44 313 5005  <br><br>[riina.tuominen@irpartners.fi](mailto:riina.tuominen@irpartners.fi)  <br><br>+358 50 553 9535 / +44 7 469 766 223  <br><br>[kare.laukkanen@irpartners.fi](mailto:kare.laukkanen@irpartners.fi) |
| **FINN Partners, US**  <br><br>**(Media)**   <br><br>Alyssa Paldo | +1 847 791-8085   <br><br>[alyssa.paldo@finnpartners.com](mailto:alyssa.paldo@finnpartners.com) |
| **Cairn Financial Advisers LLP**  <br><br>**(Nominated Adviser and Broker)**  <br><br>Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| **Sisu Partners Oy**  <br><br>**(Certified Adviser on Nasdaq First North)**  <br><br>Juha Karttunen  <br><br>Jukka Järvelä | +358 (0)40 555 4727  <br><br>+358 (0)50 553 8990 |

**About BEXMAB**  

The BEXMAB study is an open-label Phase I/II clinical trial investigating *bexmarilimab* in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of *bexmarilimab* in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

**About** ***bexmarilimab***  

*Bexmarilimab* is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. *Bexmarilimab* binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, *bexmarilimab* alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

**About Faron Pharmaceuticals Ltd**  

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is *bexmarilimab*, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. *Bexmarilimab* is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at [www.faron.com](http://www.faron.com/)

  

- - -

**MFN** is a regulatory news distribution service and it is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. The service is built to easily manage all the tasks of news distribution for listed companies.

For further information, please contact [support@modularfinance.com](mailto:support@modularfinance.com) or visit [Modular Finance](https://modularfinance.com/mfn).

View the source version on MFN: [Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress](https://mfn.se/a/faron-pharmaceuticals/faron-announces-acceptance-of-bexmarilimab-data-for-oral-presentation-at-eha-2025-congress)